{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:54:46Z","timestamp":1785887686047,"version":"3.56.0"},"reference-count":27,"publisher":"SAGE Publications","issue":"14","license":[{"start":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T00:00:00Z","timestamp":1626566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Naratriptan, marketed in a low oral dose of 2.5\u2009mg, is generally regarded as a less-effective triptan with a slower onset of action than most other triptans in the treatment of migraine attacks. In this review, naratriptan will be compared with sumatriptan, the standard triptan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Papers on pharmacodynamics and pharmacokinetics and results from comparative clinical trials with oral and subcutaneous naratriptan versus other triptans were retrieved from PubMed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Naratriptan and sumatriptan have similar effects in relevant animal models. In a randomized controlled trial, oral naratriptan 2.5\u2009mg is less effective than oral sumatriptan 100\u2009mg after both 2\u2009h and 4 h. In contrast, oral naratriptan 10\u2009mg has a similar time-effect curve as oral sumatriptan 100\u2009mg, in both its steepness and the efficacy at 2\u2009h and 4 h. Subcutaneous naratriptan 10\u2009mg (88% pain free at 2 h) was in one trial superior to subcutaneous sumatriptan 6\u2009mg (55% pain free at 2 h).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Naratriptan was marketed for the treatment of migraine attacks as the \u201cgentle triptan\u201d in a low oral dose of 2.5\u2009mg, a dose with no more adverse events than placebo. This low dose results in the slow onset of action and low efficacy of oral naratriptan, but in high doses oral naratriptan is similar to oral sumatriptan. Based on one randomized controlled trial, subcutaneous naratriptan has probably the greatest effect of any triptan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024211028959","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:45:48Z","timestamp":1626655548000},"page":"1499-1505","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A\u2009mini-review"],"prefix":"10.1177","volume":"41","author":[{"given":"Peer","family":"Tfelt-Hansen","sequence":"first","affiliation":[{"name":"Danish Headache Center, Department of Neurology, Rigshospitalet \u2013 Glostrup Hospital, University of Copenhagen, Glostrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,7,18]]},"reference":[{"key":"bibr1-03331024211028959","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/oso\/9780192632142.003.0033","volume-title":"The Triptans: Novel Drugs For Migraine","author":"Salonen R.","year":"2001"},{"key":"bibr2-03331024211028959","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140030-00004"},{"key":"bibr3-03331024211028959","doi-asserted-by":"publisher","DOI":"10.2165\/11537990-000000000-00000"},{"key":"bibr4-03331024211028959","unstructured":"A randomized, double-blind, placebo-controlled, oral sumatriptan controlled (100\u2009mg), three attacks, parallel group study, to determine the efficacy, safety and tolerability of oral naratriptan (0.1\u2009mg, 0.25\u2009mg, 1\u2009mg, and 2.5\u2009mg) in the acute treatment of migraine headache, gsk-studyregister.com\/en\/trial-details\/?id=S2WB3002 (Accessed 24 May 2021)."},{"key":"bibr5-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80068-5"},{"key":"bibr6-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.1998.550469.x"},{"key":"bibr7-03331024211028959","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060060-00003"},{"key":"bibr8-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.1.25"},{"key":"bibr9-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-14-S1-P75"},{"key":"bibr10-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03925.x"},{"key":"bibr11-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1703145.x"},{"key":"bibr12-03331024211028959","first-page":"411","volume-title":"The Headaches","author":"Saxena PR","year":"2000","edition":"2"},{"key":"bibr13-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1111\/head.12550"},{"key":"bibr14-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2000.00117.x"},{"key":"bibr15-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411417901"},{"key":"bibr16-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419828967"},{"key":"bibr17-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1002\/pds.890"},{"key":"bibr18-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.6.1485"},{"key":"bibr19-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3803184.x"},{"key":"bibr20-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14090"},{"key":"bibr21-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420956916"},{"key":"bibr22-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1111\/head.12601"},{"key":"bibr23-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1046\/0333102401021s0111"},{"key":"bibr24-03331024211028959","first-page":"CD008615","volume":"2012","author":"Derry CJ","year":"2","journal-title":"Cochrane Database Syst Review"},{"key":"bibr25-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1998.1808539.x"},{"key":"bibr26-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04078.x"},{"key":"bibr27-03331024211028959","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-007-0411-x"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211028959","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024211028959","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211028959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:49:09Z","timestamp":1777387749000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024211028959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,18]]},"references-count":27,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1177\/03331024211028959"],"URL":"https:\/\/doi.org\/10.1177\/03331024211028959","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,18]]}}}